{"page":{"totalFilteredElements":80},"studies":[{"active":true,"description":"International, multicenter, non-interventional PASS study  to evaluatemthe effectiveness and safety of elranatamab in patients with relapsed/refractory multiple myelom treated in real world settings","eudractNumber":null,"id":11259,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2025-08-01T10:04:25+02:00","shortTitle":"MagnetisMM-16","therapeutical":false,"therapyLines":[]},{"active":true,"description":"

ENCLOSE (Klinische Studiengruppe NAFLD): CK18 M30 als\nnicht-invasiver Marker für subklinische Zellschädigung – prospektive Analyse\ndes Langzeitverlaufes bei NAFLD

","eudractNumber":null,"id":2266,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"}],"mutations":[{"name":"Caspase-cleaved fragment of CK18 (M30)","id":"mt_271"}],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2016-07-01T12:46:03+02:00","shortTitle":"NAFLD CSG","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Multizentrische, länderübergreifende, prospektive, beobachtende Unbedenklichkeitsstudie zur Beschreibung der Inzidenz der Abbruchquote aufgrund von Diarrhoe innerhalb der ersten 3 Monate der Behandlung mit Neratinib bei erwachsenen Brustkrebspatienten als erweiterte adjuvante Behandlung in einem realen Umfeld: die NERLYFE-Studie","eudractNumber":null,"id":9352,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2022-06-10T10:14:43+02:00","shortTitle":"NERLYFE-Studie","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Dieses Single Patient\nRequest (SPR) / Named Patient Program (NPP) / Intermediate Expanded Access\nProgram (I-EAP) soll einen frühzeitigen Zugang zu\nNiraparib/Abirateronacetat-Kombination (JNJ- 67652000) zur Anwendung mit\nPrednison oder Prednisolon vor der Zulassung ermöglichen, um einen kritischen\nungedeckten Bedarf bei Patienten mit Prostatakrebs zu decken, die ein\nmetastasiertes kastrationsresistentes Prostatakarzinom (mCRPC) entwickelt haben\nund bei denen homologe Rekombinationsreparatur (HRR)-Genveränderungen (Keimbahn\nund/oder somatisch) positiv sind.","eudractNumber":null,"id":7946,"indications":[{"id":"pro","name":"Prostatakrebs"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2022-09-14T16:19:57+02:00","shortTitle":"NPP 67652000MPC4001","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"},{"id":"tl_9","name":"Metastatic"}]},{"active":true,"description":"Treatment and outcome of patients with advanced breast cancer: clinical research platform for real world data (OPAL) IOM-100361","eudractNumber":null,"id":4638,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"}],"mutations":[],"nctNumber":"NCT03417115","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2018-05-03T12:36:45+02:00","shortTitle":"OPAL (IOM-100361)","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Prostate Cancer Outcomes – Compare & Reduce Variation in  DKG - zertifizierten  Prostatakrebszentren

DRKS00010774
","eudractNumber":null,"id":9703,"indications":[{"id":"pro","name":"Prostatakrebs"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2023-03-15T08:27:15+01:00","shortTitle":"PCO-D Studie","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Prostate Cancer Outcomes – Compare & Reduce Variation in  DKG - zertifizierten  Prostatakrebszentren

DRKS00010774
","eudractNumber":null,"id":4239,"indications":[{"id":"pro","name":"Prostatakrebs"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2017-07-01T11:40:15+02:00","shortTitle":"PCO-D Studie","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Prostate Cancer Outcomes – Compare & Reduce Variation in  DKG - zertifizierten  Prostatakrebszentren

DRKS00010774
","eudractNumber":null,"id":10857,"indications":[{"id":"pro","name":"Prostatakrebs"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2022-04-01T08:48:22+02:00","shortTitle":"PCO-D Studie","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Prostate Cancer Outcomes – Compare & Reduce Variation in  DKG - zertifizierten  Prostatakrebszentren

DRKS00010774
","eudractNumber":null,"id":4571,"indications":[{"id":"pro","name":"Prostatakrebs"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2018-12-02T09:01:43+01:00","shortTitle":"PCO-D Studie","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Prostate Cancer Outcomes – Compare & Reduce Variation in  DKG - zertifizierten  Prostatakrebszentren

DRKS00010774
","eudractNumber":null,"id":4307,"indications":[{"id":"pro","name":"Prostatakrebs"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2017-01-03T12:47:13+01:00","shortTitle":"PCO-D Studie","therapeutical":false,"therapyLines":[]}]}